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BACKGROUND
Common variable immunodeficiency (CVID) is characterized by late-onset hypo-
gammaglobulinemia in the absence of predisposing factors. The genetic cause is 
unknown in the majority of cases, and less than 10% of patients have a family 
history of the disease. Most patients have normal numbers of B cells but lack 
plasma cells.
METHODS
We used whole-exome sequencing and array-based comparative genomic hybrid-
ization to evaluate a subset of patients with CVID and low B-cell numbers. Mutant 
proteins were analyzed for DNA binding with the use of an electrophoretic mobility-
shift assay (EMSA) and confocal microscopy. Flow cytometry was used to analyze 
peripheral-blood lymphocytes and bone marrow aspirates.
RESULTS
Six different heterozygous mutations in IKZF1, the gene encoding the transcription 
factor IKAROS, were identified in 29 persons from six families. In two families, 
the mutation was a de novo event in the proband. All the mutations, four amino 
acid substitutions, an intragenic deletion, and a 4.7-Mb multigene deletion involved 
the DNA-binding domain of IKAROS. The proteins bearing missense mutations 
failed to bind target DNA sequences on EMSA and confocal microscopy; however, 
they did not inhibit the binding of wild-type IKAROS. Studies in family members 
showed progressive loss of B cells and serum immunoglobulins. Bone marrow as-
pirates in two patients had markedly decreased early B-cell precursors, but plasma 
cells were present. Acute lymphoblastic leukemia developed in 2 of the 29 patients.
CONCLUSIONS
Heterozygous mutations in the transcription factor IKAROS caused an autosomal 
dominant form of CVID that is associated with a striking decrease in B-cell numbers. 
(Funded by the National Institutes of Health and others.)
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B-Cell Loss with Heterozygous Mutations in IK AROS
The genetic cause of many primary immunodeficiencies remains unknown. Common variable immunodeficiency (CVID) 
comprises a heterogeneous group of disorders 
characterized by the late onset of recurrent infec-
tions, hypogammaglobulinemia, and poor anti-
body response to vaccine antigens that cannot 
be explained by previous exposures, treatment, 
or infections. Some patients also have autoim-
munity, granulomatous disease, or cancer.1,2
Genomic approaches, including whole-exome 
sequencing and high-resolution array-based com-
parative genomic hybridization (CGH), have ac-
celerated the identification of genetic causes in 
patients with primary immunodeficiencies, includ-
ing CVID.3-5 Mutations in several genes, including 
ICOS, CD19, CD81, CD20, CD21, TWEAK, CTLA4, 
LRBA, GATA2, CXCL12, NFKB1, and NFKB2, have 
been associated with a CVID-like phenotype in a 
small proportion of patients.6,7 A number of 
these new disorders are autosomal dominant 
with incomplete penetrance. Often, there is 
marked variation in the clinical severity, even 
among family members with the same genetic 
defect.3-7 We used whole-exome sequencing and 
high-resolution array-based CGH to evaluate a 
subset of patients with CVID and low B-cell 
numbers.
Me thods
Study Participants
All study participants or their parents provided 
written informed consent. The study was ap-
proved by the local review boards. The probands 
in this study, Patients A1, B5, C1, D2, E1, and F2, 
were first evaluated for immunodeficiency at 
3 to 32 years of age, after recurrent or severe 
bacterial infections that were often due to Strep-
tococcus pneumoniae. All six patients had hypo-
gammaglobulinemia and decreased numbers of 
B cells, findings consistent with the diagnosis of 
CVID (Table 1, and Table S1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). CVID was subsequently 
diagnosed in Patients A2, B1, B6, C2, C3, F1, F3, 
and F4.
After IKZF1 mutations had been identified in 
the probands, they were detected in additional 
affected family members. Patients B1, B2, B3, 
F5, and F6 had a history of severe bacterial infec-
tions. Patients B4, F1, and F6 had recurrent sinus-
itis, bronchitis, or both. Patient A2 had had two 
episodes of idiopathic thrombocytopenic pur-
pura. B-cell acute lymphoblastic leukemia (ALL) 
developed in Patients B7 and F12 at 3 and 5 years 
of age, respectively. Patient B1 died from pneu-
monia at 74 years of age, and Patient B7 died 
from a relapse of B-cell ALL at 5 years of age. No 
patients showed evidence of increased suscepti-
bility to viral or fungal infections. Most of the 
patients with hypogammaglobulinemia have done 
relatively well, despite inadequate treatment with 
gamma globulin in many of them. Additional 
clinical data and the methods used for genetic 
analysis, functional studies, and flow cytometry 
are described in the Supplementary Appendix.
R esult s
Mutation Detection
Whole-exome sequencing was performed on 
DNA samples from Patients A1 and A2 and the 
unaffected mother of Patient A1; Patients B1 and 
B6; Patients C1, C2, and C3 and the healthy 
daughter of Patient C1; and Patients D2 and E1. 
Mutations in 269 genes known to be associated 
with immunodeficiency (Table S2 in the Supple-
mentary Appendix), including BTK (encoding 
Bruton’s tyrosine kinase), GATA2, CTLA4, and 
TNFRS13B (encoding TACI [transmembrane acti-
vator and calcium-modulator and cyclophilin-
ligand interactor]), were not identified in any of 
these persons. A G→T substitution at c.485 in 
Family A resulted in a substitution of leucine for 
arginine at codon 162 (R162L) in IKZF1, the gene 
encoding the transcription factor IKAROS. A G→A 
substitution at c.485 in Family B resulted in a 
substitution of glutamine for arginine (R162Q) 
at the same mutated codon found in Family A. 
In Family C, an A→G substitution in IKZF1 at 
c.500 was found, resulting in a substitution of ar-
ginine for histidine at codon 167 (H167R). A G→A 
substitution at c.551 in Family D resulted in a 
substitution of glutamine for arginine at codon 
184 (R184Q). Sanger sequencing confirmed the 
mutations in the patients and detected muta-
tions in additional affected family members. The 
mutations were de novo in Patients A1 and C1; 
however, Patient D1, the asymptomatic mother 
of Patient D2, carried the same mutation as her 
daughter (Fig. 1).
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Patient 
No.
Clinical 
Manifestations
Age at 
Onset Immunoglobulin B Cells T Cells
IgG IgA IgM CD19+ CD27+† CD3+ CD3+CD4+ CD3+CD8+
yr mg/dl % (absolute lymphocyte count/mm3)
A1 Infections 9   <33 <7 21 0.5 (17) NA 95 (3180) 34 (1128) 59 (1982)
A2 ITP Infections
 3 
 6 727‡ 7 5 0.3 (12) NA 86 (3129) 47 (1831) 34 (1319)
B1 Infections 12 386 30 60 NA NA NA NA NA
B2 Infections 6 461 36 45 3.0 (80) 15 (12) 85 (2350) 34 (950) 51 (1410)
B3 Infections 10 283 15 71  7.0 (260)  72 (187) 91 (3330) 31 (1140) 61 (2230)
B4 Infections 43 433 19 56 2.0 (50) 45 (22) 86 (2030) 23 (540) 65 (1530)
B5 Infections 3 1430‡ 21 22 2.0 (50) 3 (1) 76 (1900) 36 (900) 38 (950)
B6 Infections 1 1260‡ 12 21 1.0 (20) 17 (3) 79 (1560) 38 (750) 36 (710)
B7 B-cell ALL 3 NA NA NA NA NA NA NA NA
C1 Infections 30 887‡ 73 11 1.0 (26) NA 83 (2177) 31 (806) 50 (1300)
C2 Infections 13 1052‡ 157 12 0.2 (5) NA 83 (2049) 26 (627) 50 (1225)
C3 Infections 4 1030‡ 12 <6 0.4 (18) NA 82 (3712) 26 (1168) 48 (2147)
D1 Asymptomatic — 637 5 45  7.0 (160) NA 89 (2022) 29 (632) 63 (1397)
D2 Infections 9 42 <1 7 0.3 (9) NA 96 (3388) 40 (1416) 54 (1888)
E1 Infections 3 860‡ <1 10 0.2 (5) NA 93 (2817) 25 (787) 67 (1966)
E2 Asymptomatic — NA NA NA NA NA NA NA NA
F1 Infections 57 113 <6 14 0.8 (11) 22 (2) 66 (866) 26 (343) 38 (498)
F2 Infections 29 <7 <4 <2 1.0 (18) NA 94 (1709) 59 (1068) 35 (640)
F3 Infections 21 1010‡ <6 5 0.6 (8) 24 (2) 79 (1020) 40 (522) 38 (486)
F4 Infections 22 1010‡ <6 7 0.1 (2) 58 (1) 95 (2489) 31 (787) 65 (1686)
F5 Infections 31 382 29 21 0.5 (12) 19 (2) 87 (2078) 35 (822) 52 (1238)
F6 Infections 19 148 32 39  5.5 (138) 4 (5) 82 (2115) 48 (1231) 34 (886)
F7 Asymptomatic — 528 <6 18 0.5 (9) 18 (2) 84 (1464) 58 (996) 27 (469)
F8 Asymptomatic — 789 64 46 2.7 (89) NA 86 (2851) 54 (1525) 32 (907)
F9 Asymptomatic — 844 28 36 15.0 (354)  6 (22) 77 (1940) 34 (866) 40 (955)
 F10 Asymptomatic — 606 118 32  7.5 (187) 22 (42) 76 (1864) 44 (1068) 31 (758)
 F11 Asymptomatic — 541 120 53 17.1 (544) 15 (79) 68 (2026) 43 (1286) 22 (656)
 F12 B-cell ALL Infections
 5 
 6 590 36 13 13.7 (452)  9 (42) 75 (2292) 34 (1032) 42 (1269)
 F13 Asymptomatic — 629 28 40 15.4 (291) 12 (34) 78 (1356) 55 (953) 22 (378)
*  The most recent, comprehensive, and representative laboratory data are shown for each patient; complete laboratory data are provided in 
Table S1 in the Supplementary Appendix. Numbers in italics indicate values above the normal range, and numbers in boldface indicate val-
ues below the normal range for age-matched controls in the laboratory in which the study was performed: the National Institutes of Health 
Clinical Center (Families A and C), University Children’s Hospital Zurich (Family B), Quest Diagnostics (Family D), Oslo University Hospital 
and University of Oslo (Family E), and ARUP Laboratories (Family F). ALL denotes acute lymphoblastic leukemia, CVID common variable 
immunodeficiency, ITP idiopathic thrombocytopenic purpura, and NA not available.
†  CD27+ B cells are expressed as the percentage among CD19+ B cells. Values are included only if at least 50 CD19+ B cells were analyzed.
‡  The patient was receiving IgG replacement therapy.
Table 1. Clinical and Laboratory Characteristics of 29 Patients with Heterozygous IKAROS Mutations.*
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Whole-exome sequencing and customized 
array-based CGH were performed on a DNA sam-
ple from Patient E1. In silico copy-number varia-
tion analysis of data from whole-exome sequenc-
ing8 showed an IKZF1 intragenic heterozygous 
deletion. Sanger sequencing identified the exact 
mutation breakpoints (Fig. S1 in the Supplemen-
tary Appendix). This 16.8-kb deletion (Chr7 [hu-
man assembly GRCh37]:g.50435843_50452713del; 
NM_006060.5(IKZF1):c.1618388_589+2308del) re-
sults in the in-frame deletion of IKZF1 exons 4 
and 5. The same heterozygous deletion was de-
tected in Patient E2 (the son of Patient E1) by 
means of CGH.
CGH analysis of DNA samples from Patient 
F1, her husband, and her four children revealed 
a 4.7-Mb heterozygous deletion on chromosome 
7 in Patient F1 and three of her children (Patients 
F3, F4, and F5). The 7p12.3-p12.1 deletion involves 
11 genes (ABCA13, CDC14C, VWC2, ZPBP, C7orf7, 
IKZF1, FIGNL1, DDC, GRB10, COBL, and POM121L12). 
Only IKZF1 is known to play a role in B-cell devel-
opment and function. Multiplex ligation-depen-
dent probe amplification revealed the IKZF1 dele-
tion in nine additional family members (Fig. 1). 
No germline constitutional deletion of this re-
gion was reported in more than 8000 healthy 
controls.9 However, patients with complex genetic 
syndromes associated with total or subtotal 
chromosome 7p deletions, including one child 
with Greig cephalopolysyndactyly and ALL, have 
been described.10
IKAROS is a member of a family of hemato-
poietic zinc-finger transcription factors.11 It was 
first identified on the basis of its ability to bind 
regulatory regions of genes encoding terminal 
deoxynucleotidyl transferase (TdT) and CD3δ.12,13 
It also binds pericentromeric DNA as part of the 
NuRD (nucleosome remodeling and histone 
deacetylase) complex and can both enhance and 
repress gene transcription.14-16 The four N-termi-
nal zinc fingers of IKAROS form the DNA-
binding domain, and the two C-terminal zinc 
fingers act as a dimerization domain.11,17 Multi-
ple splice variants of IKAROS are produced; those 
that have lost the DNA-binding zinc fingers but 
have retained the dimerization zinc fingers act 
as dominant negative regulators of IKAROS 
family members.18
The missense mutations in Families A, B, and 
C were in zinc finger 2, and the mutation in 
Family D was in zinc finger 3; these two highly 
conserved domains (Fig. S1 in the Supplemen-
tary Appendix) are essential for DNA binding.15 
The deletion in Patient E1 resulted in the loss of 
zinc fingers 1, 2, and 3. Previously published 
structural studies indicate that missense muta-
tions R162L, R162Q, and R184Q occur at DNA 
contact residues, whereas the H167R mutation 
involves one of the C2H2 zinc-finger canonical 
histidines (see Fig. S2 in the Supplementary Ap-
pendix for the structure of IKAROS).15 Further-
more, these four mutations are predicted to be 
highly damaging to protein function (Fig. S3 in 
the Supplementary Appendix). These point mu-
tations were not seen in more than 64,000 ge-
nomes included in the 1000 Genomes Project 
and the Exome Aggregation Consortium (ExAC) 
database. No premature stop codons in IKZF1 
were found in these databases, and the few mis-
sense mutations reported were either very rare 
or predicted to be benign. In addition, IKZF1 is 
under strong purifying selection (Fig. S4 in the 
Supplementary Appendix), meaning that persons 
carrying dysfunctional variants tend not to sur-
vive to reproductive age. Finally, DNA from 132 
additional patients with CVID, including 21 pa-
tients with low B-cell numbers, was analyzed for 
mutations in IKZF1 by means of whole-exome 
sequencing or Sanger sequencing of exons, but 
no additional mutations were identified.
Functional Analysis of IKZF1 Mutations
Flow cytometry showed that the amount of 
IKAROS in T cells and B cells from the study 
participants with amino acid substitutions was 
equal to that in T cells and B cells from controls, 
whereas T cells and B cells from the participants 
with the large deletion had approximately half 
the normal amount of IKAROS (Fig. S5 in the 
Supplementary Appendix). To examine the sta-
bility of the proteins resulting from the four 
missense mutations in IKZF1 (R162L, R162Q, 
H167R, and R184Q) and the ability of these 
proteins to dimerize with wild-type IKAROS and 
enter the nucleus, we transfected HEK293T cells 
with wild-type and mutant expression vectors. 
Western blot analysis of extracts from the cyto-
plasm and nucleus of the transfected cells 
showed that these mutant proteins were stable, 
The New England Journal of Medicine 
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were dimerized with wild-type IKAROS, and were 
able to migrate to the nucleus (Fig. S6 in the 
Supplementary Appendix). The nuclear extracts 
from transfected cells were used in an electro-
phoretic mobility-shift assay (EMSA) to evaluate 
the ability of the mutant proteins to bind an 
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IKAROS consensus-binding sequence (IK-bs4)15 
and a probe from the pericentromeric region of 
human chromosome 8 (γSat8).19 The four pro-
teins resulting from missense mutations failed 
to bind these probes (Fig. S7A and S7B in the 
Supplementary Appendix). To determine whether 
the amino acid substitutions resulted in a domi-
nant negative effect and to mimic the heterozy-
gous state, we performed EMSAs with nuclear 
extracts from human embryonic kidney 293T 
(HEK293T) cells transfected with vector express-
ing 100% wild-type IKAROS or vectors express-
ing 50% wild-type and 50% mutant IKAROS. 
DNA binding was reduced by 38 to 74% in the 
cells transfected with the 50% wild-type and 
50% mutant vectors, as compared with the cells 
transfected with 100% wild-type vector. This 
finding was consistent with the reduction in the 
amount of wild-type vector used in transfection 
(Fig. S7A and S7B).
Confocal microscopy showed that transfected 
NIH-3T3 cells expressing wild-type IKAROS had 
the punctate staining pattern that is characteris-
tic of pericentromeric heterochromatin binding 
and localization (Fig. S7C in the Supplementary 
Appendix). In contrast, the four proteins result-
ing from missense mutations had diffuse nuclear 
staining. When the NIH-3T3 cells were trans-
fected with equal amounts of the vector express-
ing wild-type IKAROS and the vector expressing 
mutant IKAROS, the staining pattern was simi-
lar to that seen in cells transfected with only the 
vector expressing wild-type IKAROS (Fig. S7D in 
the Supplementary Appendix). Similar results 
were obtained when HEK293T cells were trans-
fected (Fig. S8 in the Supplementary Appendix). 
The combined results of the EMSAs and confo-
cal microscopy are consistent with the hypothe-
sis that the four proteins resulting from mis-
sense mutations do not have a dominant negative 
effect.
To compare the mutations found in these 
patients with previously described mutations in 
IKZF1, we performed an EMSA and confocal 
microscopy with the use of vectors expressing 
N159A, an experimentally generated in vitro 
mutation15; H191R, an ethylnitrosourea-induced 
murine mutation20; and Y210C, a mutation in 
zinc finger 4 that was identified in a critically ill 
premature infant with pancytopenia.21 The ab-
normal EMSA results and perinuclear localiza-
tion for the N159A and H191R mutations were 
similar to the findings with the R162L, R162Q, 
H167R, and R184Q mutations. The Y210C muta-
tion showed decreased but not absent DNA bind-
ing on an EMSA. Primary T cells from the in-
fant, who was heterozygous for the Y210C allele, 
were reported to show abnormal subcellular lo-
calization of IKAROS; however, we saw normal 
pericentromeric localization of the protein with 
the Y210C mutation when expressed alone or in 
the presence of the wild-type allele in transfect-
ed NIH-3T3 cells (Fig. S9 in the Supplementary 
Appendix).
Laboratory Findings
There was some variation in laboratory findings 
among the study participants. However, 26 of 
the 27 patients for whom pretreatment data were 
available had a marked decrease in at least two 
of the three major immunoglobulin isotypes 
(IgG, IgM, and IgA); 23 had a decrease in all 
three isotypes, and 6 with panhypogamma-
globulinemia had a serum IgG level of less than 
150 mg per deciliter before treatment with 
gamma globulin was started (Table 1). Only 1 pa-
tient (at 5 years of age) had normal findings for 
the three major immunoglobulin isotypes. Assess-
ment of antibodies to vaccine antigens, which 
was performed in 8 patients, showed an absence 
of antibodies in 6 patients, progressive loss of 
antibodies in 1, and normal titers in 1. At their 
Figure 1 (facing page). Mutation in IKAROS (IKZF1)  
in Families with Common Variable Immunodeficiency.
Panel A shows the pedigrees of the six families. Circles 
and squares denote female and male family members, 
respectively. Black symbols represent family members 
with a heterozygous mutation in IKZF1, and slashes 
 indicate deceased family members. In Family F, the 
 diamond with the number in it indicates the number  
of family members (male or female) who were not 
screened. Arrows indicate the probands. The specific 
complementary DNA (IKZF1 transcript variant 
NM_006060) and protein mutation are indicated 
above each pedigree. Mut denotes mutation, and WT 
wild type. Panel B, top, shows the exon structure of 
full-length IKAROS isoform 1 in light-gray boxes (IKZF1 
transcript variant NM_006060), with the zinc fingers 
(ZFs) indicated in dark-gray boxes. The sites of the 
mutations in Families A, B, C, and D and the deletion 
of c.161-8388_589+2308del in IKZF1 in Family E are 
shown. The lower part of the panel shows a schematic 
representation of the 4.7-Mb deletion on the short arm 
of chromosome 7 (7p12.3-p12.1) in Family F, with the 
deletion indicated in red.
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most recent evaluation, 14 patients had a CD19+ 
cell count of less than 1% in peripheral blood; 
however, CD19+CD27+ memory B cells were 
readily detectable in the 14 patients in whom 
they were analyzed. When plotted against age, 
the serum IgG level showed a progressive de-
cline (Fig. 2). A similar finding was noted when 
the number of CD19+ B cells was evaluated 
(Table 1, and Table S1 in the Supplementary Ap-
pendix).
T-cell studies showed a consistent increase in 
CD8+ T cells with reversed CD4:CD8 ratios in 10 
of 13 participants with DNA-binding defects in 
IKAROS (e.g., amino acid substitutions or exon 
4 and 5 deletion) and in 3 of 13 patients with 
complete deletion of IKZF1 (P = 0.01 on the basis 
of a two-tailed Fisher’s exact test) (Table 1 and 
Fig. 2, and Table S1 in the Supplementary Ap-
pendix). The CD8+ T cells were predominantly 
naive cells (CD62L+CD45RA+) and central mem-
ory cells (CD62L+CD45RA−) in the 6 patients 
who were assessed for these markers. Both 
CD4+ and CD8+ cells appeared to be polyclonal 
on cytometric analysis of Vβ flow (Fig. S10 in 
the Supplementary Appendix) and studies of T-
cell receptor gamma-chain rearrangement. Pro-
liferation of T-cells and Fas-mediated apoptosis 
were similar in patients and controls (Fig. S11 in 
the Supplementary Appendix). Polymerase-
chain-reaction assays for cytomegalovirus and 
Epstein–Barr virus were negative in the 6 pa-
tients with reversed CD4:CD8 ratios who were 
evaluated. The number of natural killer cells 
ranged from the high end to the low end of the 
normal range (Table S1 in the Supplementary 
Appendix).
Bone marrow aspirates were available from 
two members of Family C (Patient C1, at the age 
of 45 years, and Patient C2, at the age of 16 
years), both of whom had a CD19+ B-cell count 
of 1% or less in peripheral blood. Normal num-
bers of CD34+ and CD138+ plasma cells were 
found in the bone marrow (Fig. 3A), but there 
was a marked decrease in pro-B cells (defined by 
coexpression of CD34 and CD19) and earlier 
precursors (expressing surface CD34 and cyto-
plasmic TdT in the absence of CD19) (Fig. 3B).22 
Both the number of TdT+ cells and the intensity 
of TdT expression were decreased. Because TdT 
is a direct target of IKZF1,12 we compared the 
number of TdT-mediated additions in immuno-
globulin heavy-chain transcripts from comple-
mentary DNA obtained from Patients B5 and C1 
with the number in four healthy controls and 
two patients with mutations in BTK who had a 
similar number of peripheral-blood B cells. In 
the patients and the controls, the number of 
TdT-mediated additions was within the normal 
range23 (Table S3 in the Supplementary Appen-
dix). The small number of CD34−CD19+ cells in 
bone marrow aspirates from Patients C1 and C2 
were equally divided between pre-B cells that 
were negative for surface immunoglobulin and 
immature B cells that were positive for surface 
immunoglobulin (Fig. 3B), indicating that the 
block in B-cell differentiation was not complete 
and some precursors were able to differentiate 
into B cells.
Discussion
CVID is characterized by late-onset hypogam-
maglobulinemia and a poor antibody response 
to infectious and vaccine antigens.1,2 The genetic 
cause is unknown in the majority of cases, and 
less than 10% of patients have a family history 
of the disease. Most patients have normal num-
bers of B cells but lack plasma cells. This study 
documents the progressive loss of serum immu-
noglobulins and B cells in a subset of patients 
with CVID associated with heterozygous muta-
tions in IKZF1. Clinical and laboratory findings 
varied among these persons, particularly during 
childhood. However, 13 of the 14 study partici-
pants who were older than 25 years of age were 
clinically symptomatic, and all these adults had 
laboratory evidence of immunodeficiency. Some 
of the children and adults had a surprisingly mild 
clinical course despite low concentrations of se-
rum immunoglobulins, decreased numbers of 
B cells, and inadequate treatment with gamma 
globulin. One adult patient (D1) and several chil-
Figure 2 (facing page). Low Serum IgG Levels and 
 Progressive Loss of Peripheral-Blood B-Cell Counts  
in Patients with IKZF1 Mutations.
The symbols represent individual family members, 
with black symbols indicating those who were asymp-
tomatic; gray shading represents mean values ±1 SD  
in healthy controls. Only patients who were not being 
treated with gamma globulin are included in the data 
shown for IgG levels.
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dren with IKAROS deficiency were asymptom-
atic, which suggests that penetrance is incom-
plete (Fig. S12 in the Supplementary Appendix); 
however, clinical manifestations may appear as 
late as the sixth decade of life. Nevertheless, 
several observations indicate that the clinical 
penetrance of IKZF1 mutations is very high. The 
occurrence of de novo mutations in two of the 
six kindreds and the strong purifying (or nega-
tive) selection for IKZF1 indicate that there is 
selection against these mutations in evolution. 
In addition, IKZF1 ranks second to RPSA (and 
higher than CTLA4 and GATA2) in terms of nega-
tive selection among the 15 known autosomal 
dominant primary immunodeficiencies caused 
by haploinsufficiency.24-27
The mechanism of dominance in Family F is 
most likely haploinsufficiency on the basis of 
the complete deletion of one of the IKZF1 alleles; 
however, the other genes included in the dele-
Figure 3. Immunohistochemical Analysis of Bone Marrow–Biopsy Specimens and Flow-Cytometric Analysis of Bone 
Marrow Aspirates.
Panel A shows immunohistochemical staining for CD34+ cells (hematopoietic stem cells) and CD138+ cells (plasma 
cells) in bone marrow–biopsy specimens from a healthy control, Patients C1 and C2, and a patient with typical com-
mon variable immunodeficiency (CVID). CD34+ and CD138+ cells are present in the control and in Patients C1 and 
C2 (red staining); CD34+ cells are present but CD138+ cells are absent in the patient with typical CVID. Panel B shows 
the results of flow-cytometric analysis of bone marrow aspirates from a healthy control and Patient C2. A total of 
500,000 events were analyzed for both persons. A gate was used that collected all cells that were positive for CD34, 
CD19, or both (top and middle graphs) and cells that were negative for CD34 but positive for CD19 (bottom graph). 
The graph at the top shows a marked decrease in CD34+CD19+ pro-B cells in Patient C2 as compared with the con-
trol. The middle graph shows that precursors of pro-B cells that express CD34+ and cTdT+ (cytoplasmic terminal 
deoxynucleotidyl transferase) but lack CD19 are also decreased. The bottom graph shows that the relative numbers 
of pre-B cells (CD34−CD19+sIg− [surface immunoglobulin]) to immature B cells (CD34−CD19+sIg+), as documented 
by the expression of surface kappa or surface lambda, in the patient is similar to that in the control, although the total 
number of cells in both populations is decreased in the patient.
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tion may contribute to the phenotype. The situ-
ation is also complex in Families A, B, C, and D, 
in which the mutant allele results in a stable 
protein that is able to dimerize with wild-type 
IKAROS but is unable to bind target DNA (Fig. 
S6 and S7, respectively, in the Supplementary 
Appendix). On the basis of previously reported 
data,15 IKAROS protein lacking zinc fingers 1, 2, 
and 3, as in Family E, behaves similarly to the 
missense proteins in Families A through D. Be-
cause IKAROS functions as a dimer, one might 
expect these proteins to act in a dominant nega-
tive fashion, similar to that recently reported for 
patients with heterozygous mutations in the 
DNA-binding domain of E47,28 another tran-
scription factor required for B-cell development. 
However, both EMSAs and confocal microscopy 
showed that the mutant proteins do not inhibit 
the DNA binding of wild-type IKAROS (Fig. S7). 
Furthermore, the clinical and laboratory find-
ings in the patients with defects restricted to the 
DNA-binding domain of IKAROS are similar to 
those seen in the patients with complete dele-
tion of the gene.
In contrast, the patients with mutations in 
the DNA-binding domain of IKAROS had a more 
striking increase in the number of CD8+ cells 
than did the patients with complete gene dele-
tion. A recent study suggests that murine CD8+ 
cells that are haploinsufficient for Ikaros pro-
duce increased amounts of autocrine interleu-
kin-2 when stimulated.29 This may explain the 
increased numbers of CD8+ cells, suggesting a 
relatively T-cell–specific dominant negative effect 
in patients with mutations resulting in stable 
proteins that fail to bind DNA.
Y210C, a different heterozygous de novo mu-
tation in IKZF1, was reported in a premature 
infant with pancytopenia and complete loss of 
B cells and natural killer cells.21 The pathophys-
iological features and severity of the phenotype 
in this infant cannot be readily explained but 
may have been due to defects in functions of 
IKAROS that are unrelated to DNA binding or to 
additional genetic or nongenetic modifying fac-
tors. One of the more striking features of re-
cently identified autosomal dominant genetic 
defects is the marked heterogeneity in phenotype 
caused by mutations in the same gene. In some 
instances, this heterogeneity results from the fact 
that different mutations in the same gene have 
very different effects on protein function. In other 
instances, modifying genetic factors, environ-
mental or infectious exposures, or even the age 
at which environmental or infectious exposures 
occur may influence the clinical features.7
S. pneumoniae is a common infectious organ-
ism in patients with hypogammaglobulinemia, 
poor antibody function, and low B-cell num-
bers30; it also was common in our patients who 
had mutations in IKZF1. There was no evidence 
of increased susceptibility to viral or fungal in-
fections in any of these patients. Thus, like 
other types of CVID, IKAROS deficiency should 
be viewed as a “predominantly antibody defi-
ciency” on the basis of the International Union 
of Immunological Societies classification of pri-
mary immunodeficiency diseases.4
There are several murine models of Ikaros 
deficiency.20,31-33 The most severe phenotype is 
associated with an amino acid substitution 
(H191R) in zinc finger 3 of the DNA-binding 
domain.20 Homozygosity for this mutation is 
lethal to the embryo because of anemia. Hetero-
zygous mice have normal numbers of peripheral-
blood B cells but reduced numbers of B-cell 
precursors in the bone marrow. Heterozygous 
Ikzf1H191R mice or Ikzf1del(ex3-ex4) mice (mice with a 
mutation that deletes three of the N-terminal 
zinc fingers) have a high incidence of T-cell leu-
kemia.20,34 In contrast, somatic loss-of-function 
and dominant negative mutations in IKZF1 are 
predominantly associated with B-cell leukemias 
in humans.35-38 Furthermore, polymorphic vari-
ants in IKZF1 that decrease the number of tran-
scripts constitute a risk factor for both pediatric 
and adult B-cell ALL.39 In our study, typical child-
hood B-cell ALL developed in 2 of the 29 pa-
tients with germline heterozygous mutations in 
IKZF1. Thus, the penetrance for acquired hypo-
gammaglobulinemia was higher than that for 
leukemia. This finding is compatible with data 
suggesting that mutations in IKZF1 are not the 
initiating event in leukemias.38 Leukemias associ-
ated with somatic mutations in IKZF1 lead to over-
expression of hematopoietic stem-cell genes.37,40 
Overexpression of stem-cell genes in patients 
with germline heterozygous mutations in IKZF1 
may result in stem-cell exhaustion (i.e., excessive 
proliferation of stem cells, resulting in prema-
ture senescence or anergy). This in turn could 
cause an acceleration of the normal decrease in 
B-cell production that occurs with age.41
We speculate that the relatively mild clinical 
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phenotype in the patients with heterozygous 
mutations in IKZF1 may be due to the production 
of functional antibodies early in life, with the 
generation of some CD27+ memory B cells and 
the persistence of long-lived plasma cells in the 
bone marrow. The presence of these CD27+ 
memory B cells and plasma cells, in the context 
of very low numbers of peripheral-blood B cells, 
reversed CD4:CD8 ratios, and a family history 
compatible with autosomal dominant inheri-
tance, distinguishes patients with IKAROS mu-
tations from other patients with CVID.
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